Last reviewed · How we verify
bortezomib + rituximab
Bortezomib inhibits the proteasome to trigger cancer cell death, while rituximab targets CD20 on B cells to enhance immune-mediated tumor destruction.
Bortezomib inhibits the proteasome to trigger cancer cell death, while rituximab targets CD20 on B cells to enhance immune-mediated tumor destruction. Used for B-cell non-Hodgkin lymphoma, Mantle cell lymphoma.
At a glance
| Generic name | bortezomib + rituximab |
|---|---|
| Sponsor | Jonsson Comprehensive Cancer Center |
| Drug class | Proteasome inhibitor + monoclonal antibody combination |
| Target | 26S proteasome (bortezomib); CD20 (rituximab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bortezomib is a proteasome inhibitor that blocks protein degradation pathways, leading to accumulation of pro-apoptotic proteins and cancer cell death. Rituximab is a chimeric monoclonal antibody against CD20 that depletes B cells and enhances antibody-dependent cellular cytotoxicity. Together, they provide complementary mechanisms targeting both intrinsic apoptosis and B-cell malignancy.
Approved indications
- B-cell non-Hodgkin lymphoma
- Mantle cell lymphoma
Common side effects
- Peripheral neuropathy
- Thrombocytopenia
- Neutropenia
- Anemia
- Nausea/vomiting
- Diarrhea
- Fatigue
- Infusion reactions
Key clinical trials
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma (PHASE2)
- Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (PHASE1)
- Nemtabrutinib, Bortezomib, and Rituximab for WM (PHASE2)
- Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia (PHASE2)
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) (PHASE2)
- Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (PHASE2)
- The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bortezomib + rituximab CI brief — competitive landscape report
- bortezomib + rituximab updates RSS · CI watch RSS
- Jonsson Comprehensive Cancer Center portfolio CI